SCHEMBL6406510

SCHEMBL6406510

CC(=O)c1ccc(S(=O)(=O)Cl)cc1.CC(=O)c1ccc(S(=O)(=O)N(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
HSD17B10 Q99714 2/20 0.50
SMN1; SMN2 Q16637 5/20 0.49
ALDH1A1 P00352 5/20 0.47
KMT2A Q03164 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
PKM P14618 1/20 0.47
RECQL P46063 1/20 0.47
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ATM Q13315 1/20 0.45
TP53 P04637 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5561006 0.91 SMN1; SMN2 (0.56) MAPTHSD17B10SMN1; SMN2ALDH1A1KMT2A
SCHEMBL343359 0.87 MAPT (0.52) MAPTHSD17B10SMN1; SMN2ALDH1A1KMT2A
SCHEMBL21244024 0.85 LMNA (0.59) MAPTHSD17B10SMN1; SMN2ALDH1A1KMT2A
SCHEMBL6406201 0.79 GSK3B (0.47) MAPTHSD17B10SMN1; SMN2ALDH1A1KMT2A
SCHEMBL2517845 0.78 MAPT (0.55) MAPTHSD17B10SMN1; SMN2ALDH1A1KMT2A
SCHEMBL5249012 0.77 SMN1; SMN2 (0.57) MAPTHSD17B10SMN1; SMN2ALDH1A1NPSR1
SCHEMBL34672 0.76 ALDH1A1 (0.66) MAPTHSD17B10SMN1; SMN2ALDH1A1KMT2A
SCHEMBL5563981 0.75 ALDH1A1 (0.50) MAPTHSD17B10SMN1; SMN2ALDH1A1KMT2A
SCHEMBL4639473 0.74 CA2 (0.59) MAPTHSD17B10SMN1; SMN2ALDH1A1NPSR1
Lithium Ion SCHEMBL22638688 0.74 CA1 (0.61) MAPTHSD17B10SMN1; SMN2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides SMITHKLINE BEECHAM PLC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides CD22, CD2, NEU3 MAPT 4864/4885HSD17B10 960/4885SMN1; SMN2 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.